Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

The scientists at the University of California, San Francisco, and Johns Hopkins University in Baltimore injected an ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.86, ...

Representatives of Russian patent unions have sent an appeal to the Russian Scientific Center for Expertise of Medical ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including Skyclarys and Spinraza, rose 33% to $563 million in the quarter. Revenue rose 6% to ...

Alongside Skyclarys, Biogen’s rare disease business is headed by spinal muscular atrophy treatment Spinraza (nusinersen). Spinraza generated global Q1 2025 sales of $423.9m, up from $341.3m in ...

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...

Biogen Q1 EPS hit $3.02 vs. $2.52 estimate; revenue rose 6% to $2.43 billion, beating the $2.23 billion consensus. Rare disease sales rose 33% to $563 million; Spinraza revenue climbed to $423.9 ...

Sales of Biogen’s spinal muscular atrophy drug, Spinraza, improved in the fourth quarter due to higher sales in the United States, as higher pricing offset the negative impact of a decrease in ...

Biogen is really a tale of two companies ... And actually in line pretty much with the SPINRAZA launch, I wasn't here for that, but as we've gone back and looked at it, the SPINRAZA launch ...

Alongside Skyclarys, Biogen’s rare disease business is headed by spinal muscular atrophy treatment Spinraza (nusinersen). Spinraza generated global Q1 2025 sales of $423.9m, up from $341.3m in Q1 2024 ...